logo-loader
viewImugene Ltd

Imugene reveals new clinical data for HER-Vaxx vaccine showing cancer-fighting response

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers.

cancer cells
Phase 2 study is scheduled to complete in 2020

Imugene Ltd (ASX:IMU) has revealed new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing continued positive cancer-fighting antibody and clinical response rates in patients.

Notably, the patients have maintained strong and high levels of HER-2 targeting antibodies indicating a durable response is present with no resistance developed.

In cohort 3, patients that are receiving the optimal biological dose, and selected Phase 2 dose, one patient has seen a total tumour reduction of almost 80% from baseline CT scan with one out of four of their lesions becoming unmeasurable at Day 266 visit.

 

Imugene managing director and chief executive officer Leslie Chong said: “This latest presentation from the HER-Vaxx Phase 1b study further reinforces the very good early results and ongoing interest among the international oncology community in our potentially promising B-cell platform cancer vaccine and clinical development strategy.”

READ: Imugene presents new HER-Vaxx cancer vaccine results

The positive new data was presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona Spain over the weekend.

The data will be published in the prestigious Annals of Oncology after the congress.

The Phase 1b HER-Vaxx study in metastatic gastric cancer patients overexpressing the HER-2 protein completed enrolment in late 2018 and reported no safety or toxicity issues.

All evaluable patients showed increased antibody responses. The Phase 2 study began enrolment in March 2019 and is scheduled to complete in 2020.

Background

Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu.

It has been shown in pre-clinical studies and now in Phase I studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Quick facts: Imugene Ltd

Price: 0.037 AUD

ASX:IMU
Market: ASX
Market Cap: $134.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development...

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine.   The company had a pre-investigational new drug meeting with the US Food and Drug Administration...

on 03/19/2019

3 min read